ACM Global Central Laboratory Appoints Alexander Van Amerongen, MD as Director of Anatomic Pathology

ACM Global Central Laboratory Appoints Alexander Van Amerongen, MD as Director of Anatomic Pathology

Rochester, NY, Aug. 27, 2013 – ACM Global Central Lab, a central lab that specializes in delivering high quality testing services designed to optimize clinical trial outcomes, today announced the newest member of its Medical Team, Alexander van Amerongen, MD as director of anatomic pathology. Dr. van Amerongen brings extensive pathology and cytology experience to ACM Global, having worked in both hospitals and private laboratories for more than fourteen years. He will be responsible for ensuring the quality of ACM Global's pathology and cytology services.

"We are excited to welcome such a well-regarded pathologist to our medical team," said John D'Souza, MD, Vice President, Medical Laboratory Affairs and Medical Director at ACM Global Central Laboratory. "Having a full-time staff of board-certified pathologists on-site not only gives us the ability to perform all pathology testing and analysis from a single location, which ensures clients receive consistent and reliable test results more quickly, but also gives them greater access to expert advice on test selection and interpretation. The addition of Dr. van Amerongen enhances these abilities."

Dr. van Amerongen is certified by the American Board of Pathology in anatomic pathology, clinical pathology and cytopathology and received his doctor of medicine from the University of South Dakota School of Medicine, where he also completed his residency in anatomic and clinical pathology. He completed a cytopathology fellowship at the University of Texas.

About ACM Global Central Lab

ACM Global Central Laboratory specializes in delivering high quality central laboratory testing services designed to optimize clinical trial outcomes. Through a powerful combination of robust global capabilities, operational and scientific expertise and unsurpassed service, ACM Global acts as an extension of our clients' clinical teams to develop and execute smarter testing strategies that deliver reliable outcomes for their clinical development programs. Operating in more than 60 countries, ACM Global's analytical team performs more than 15 million diagnostic tests each year from a test menu with more than 1,500 tests spanning all medical disciplines, including pathology, microbiology and molecular diagnostics, flow cytometry, specialized biomarkers, and pharmacogenomics.

For more information, visit www.acmgloballab.com, our Central Labs in Focus blog or call +1 866 405 0400. 

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.